Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Totaal lichaamsvet grotere risicofactor voor borstkanker dan buikvet
jun 2017 | Borstkanker